Sherbrooke Park Advisers LLC Supernus Pharmaceuticals, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $436 Billion
- Q3 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 16,956 shares of SUPN stock, worth $615,163. This represents 0.12% of its overall portfolio holdings.
Number of Shares
16,956
Previous 15,532
9.17%
Holding current value
$615,163
Previous $415 Million
27.25%
% of portfolio
0.12%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
281Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$377 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$222 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$185 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$105 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$95.5 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.94B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...